Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
19 hedge funds and large institutions have $21.5M invested in Nexvet Biopharma plc Ordinary Shares in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
6% more funds holding
Funds holding: 18 → 19 (+1)
29% less capital invested
Capital invested by funds: $30.1M → $21.5M (-$8.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$108K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$64.8K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$36.3K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31.7K |
| 5 |
Citigroup
New York
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$675K |
| 2 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$298K |
| 3 |
CI
Cowen Inc
New York
|
-$22.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.39K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.76K |
NVET Hedge Fund Activity: Q3 2015 in Review
19 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q3 2015, worth a combined $21.5M — down 29% from $30.1M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NVET positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $108K. The largest seller was Jennison Associates, cutting an estimated $675K.
- 19 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q3 2015, up from 18 in Q2 2015.
- Funds reported $21.5M of Nexvet Biopharma plc Ordinary Shares stock for Q3 2015, down 29% quarter-over-quarter.
- 2 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q3 2015 and 1 closed out, a net change of +1 holder.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q3 2015 was Virtu KCG Holdings, an estimated $108K added.
- The largest Nexvet Biopharma plc Ordinary Shares seller in Q3 2015 was Jennison Associates, an estimated $675K sold.
Based on aggregated 13F filings for Q3 2015.